Today we have a small company with a novel approach based on solid science that we did not want to skip because we know that today or tomorrow, the biotechnology revolution will reveal the secrets behind this ugly condition, and develop a successful treatment that would defeat it. 

INmune Bio NEWS

Today’s news comes from the small firm INmune BIO (INMB) – a clinical-stage immunology firm focused on developing treatments that harness a patient’s innate immune system to fight disease.

INmune Bio has two product platforms:

• The DN-TNF Product Platform, which utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s (XPro595) and NASH (LIVNate™).
• The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate the minimal residual disease in patients with cancer. 

INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.

XPro1595 Results and Analysis

The reported clinical results demonstrating that the firm’s lead drug candidate, XPro1595, decreases neuroinflammation in patients with Alzheimer’s disease. Interim results from a Phase Ib clinical trial show that treatment with XPro1595 decreases white matter free water, a biomarker of neuroinflammation measured by MRI.

XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that acts differently than currently existing TNF inhibitors in that it neutralizes soluble TNF (sTNF) without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro1595 could have beneficial effects in patients with Alzheimer’s disease by decreasing neuroinflammation.  

INmune compared biomarker data obtained from six patients treated with XPro1595 for 12 weeks with data from 25 Alzheimer’s patients from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) that are part of a natural history database in patients with Alzheimer’s.

The results demonstrate that over a 12-week period, whole-brain inflammation increased by 5.1% in the ADNI patients compared to an increase of 1.7% and a decrease of 2.3% in patients treated weekly with 0.3mg/kg or 1.0mg/kg of XPro1595, respectively.

A more detailed analysis revealed a 40.6% reduction in neuroinflammation in the Arcuate Fasciculus in patients treated with XPro1595. The Arcuate Fasciculus is a major white matter anterior/posterior tract (white matter bundle) containing long and short fibers that connect the frontal, parietal and temporal lobes and are important for language and short-term memory. By contrast, the ADNI cohort had a 4.6% increase in Arcuate Fasciculus neuroinflammation.

Quotes

CJ Barnum, Ph.D., Director of Neuroscience at INmune stated that the firm’s encouragement by these findings at such an early stage in a clinical trial. He said, “Not only do we see a clear reduction in neuroinflammation, but we also know where in the brain this is occurring, which may inform us on the domains of cognition that might be affected.” 

According to Sharon Cohen, M.D., FRCPC, a neurologist and Medical Director of Toronto Memory Program who is not involved with the clinical trial, said, “The preliminary results from INmune Bio’s Phase Ib study add to the growing enthusiasm for tackling neuroinflammation in the treatment of Alzheimer’s disease. Furthermore, MRI assessment of free water content in the brain holds promise as an exciting surrogate marker for tracking the impact of such treatment.”  

XPro1595 is currently being evaluated in Phase Ib clinical trial in Alzheimer’s disease patients who have biomarkers of inflammation to determine if neutralizing soluble TNF can decrease those biomarkers of neuroinflammation. There cannot be any assurance about the results of this trial. 

To learn more about the clinical trials, please visit www.inmunebio.com.  

Prohost Observations 

We appreciated what we heard and read about the XPro1595 approach for treating Alzheimer’s Disease. The product’s action and effect make sense, as the theories behind the use of the INmune Bio product makes sense.

Our eyes and ears are wide open for the details of the results from the upcoming higher phases of trials.

We are not only encouraged by what we observed but also thrilled for this new approach towards treating, or improving, the memory of Alzheimer’s Disease patients.